View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
July 19, 2018

Blade Therapeutics starts Phase l trial of BLD-2660 for fibrosis

Blade Therapeutics has commenced a Phase l clinical trial to investigate the safety and pharmacokinetics (PK) of BLD-2660 for the treatment of fibrosis.

Blade Therapeutics has commenced a Phase l clinical trial to investigate the safety and pharmacokinetics (PK) of BLD-2660 for the treatment of fibrosis.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Fibrosis is the development of additional fibrous connective tissue in an organ or tissue in a reparative or reactive process.

As part of the first-in-human, placebo-controlled, dose-escalation Phase l trial, BLD-2660 will be orally administered to healthy subjects.

The trial is being conducted in Australia and expected to provide initial results by the last quarter of this year.

Blade Therapeutics CEO Wendye Robbins said: “BLD-2660 has shown remarkable anti-fibrotic properties in multiple preclinical disease models.

“BLD-2660 has shown remarkable anti-fibrotic properties in multiple preclinical disease models.”

“We believe it will be an effective treatment option with a favourable safety profile for patients suffering from debilitating fibrotic diseases. By initiating the clinical trial in Australia, we are able to expedite our development timelines, work with top clinicians, and take advantage of favourable government rebates.

“We plan to file a US Investigational New Drug Application (IND) with human safety and PK data by the end of the year, which we anticipate will allow us to move BLD-2660 into human proof-of-concept studies in 2019.”

BLD-2660 is an optimised small molecule inhibitor of dimeric calpains, which are non-lysosomal calcium-dependent proteases.

In a number of previous biochemical studies, BLD-2660 demonstrated potent and selective inhibition of calpains 1, 2, and 9.

Developed using insights from the US’ Johns Hopkins University School of Medicine to discover new therapies that can broadly modulate fibrosis, and thereby contribute to the treatment of diverse diseases, BLD-2660 has also showed its effectiveness in various animal models of pulmonary, skin, and liver fibrosis.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU